GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent
AssigneesUniversity of Iowa Research Foundation, The United States of America as represented by the Department of Veterans Affairs
InventorsJack T. Stapleton, Nirjal Bhattarai, Jinhua Xiang, James H. McLinden
Life of this patent
Estimating the term…
Abstract
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.
Claims19
A method of inhibiting immune cell activation comprising administering to a mammalian subject in need thereof a GBV-C E2 peptide or polypeptide, said peptide or polypeptide comprising SEQ ID NO:
- 8 and no more than 250 consecutive residues of GBV-C E2.
A method of inhibiting IL-2 release, inhibiting inflammation, and/or inhibiting STATS-mediated signaling in a mammalian subject comprising administering to said subject a peptide or polypeptide, said peptide or polypeptide comprising SEQ ID NO:
- 8 and no more than 250 consecutive residues of GBV-C E2.
A pharmaceutical formulation comprising an isolated peptide comprising (a) SEQ ID NO:
- 8 and no more than 250 consecutive residues of GBV-C E2 fused to a cell permeability peptide;
- and (b) a pharmaceutically acceptable diluent, carrier or buffer.
Dependencies are inferred from the claim text.